{"id":"bevacizumab-awwb","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Proteinuria"},{"rate":"5-15","effect":"Hemorrhage"},{"rate":"5-10","effect":"Thromboembolism"},{"rate":"1-2","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Wound healing complications"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":{"setId":"0a562b4e-67ce-4bab-852c-d9ee71e55fb8","title":"MVASI (BEVACIZUMAB-AWWB) INJECTION, SOLUTION [AMGEN, INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug blocks VEGF, a key signaling molecule that promotes the formation of new blood vessels that tumors need to grow and spread. By preventing VEGF from binding to its receptors on endothelial cells, bevacizumab-awwb starves tumors of their blood supply, slowing or stopping tumor growth. Bevacizumab-awwb is a biosimilar to the reference bevacizumab product, manufactured by Amgen.","oneSentence":"Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:50.069Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-squamous non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Recurrent glioblastoma"},{"name":"Metastatic renal cell carcinoma"},{"name":"Persistent, recurrent, or metastatic cervical cancer"}]},"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT04181060","phase":"PHASE3","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-28","conditions":"Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":300},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT05211323","phase":"PHASE2","title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-07","conditions":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer","enrollment":88},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2431},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT06580314","phase":"PHASE3","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-03-12","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014","enrollment":880},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT04919629","phase":"PHASE2","title":"APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-04-27","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":60},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT05039801","phase":"PHASE1","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-09","conditions":"Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT02971501","phase":"PHASE2","title":"Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-27","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8","enrollment":7},{"nctId":"NCT05231122","phase":"PHASE2","title":"Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-03-12","conditions":"Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma","enrollment":80},{"nctId":"NCT04721132","phase":"PHASE2","title":"Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-10","conditions":"Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8","enrollment":16},{"nctId":"NCT00433511","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11-02","conditions":"Breast Adenocarcinoma","enrollment":4994},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT04837716","phase":"PHASE1","title":"Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT05096715","phase":"PHASE1","title":"Atezolizumab+Bevacizumab+SBRT in Unresectable HCC","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-08-23","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT04109924","phase":"PHASE2","title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-27","conditions":"Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT06469281","phase":"PHASE1","title":"A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-06","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer","enrollment":90},{"nctId":"NCT07166406","phase":"PHASE3","title":"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-10-07","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":252},{"nctId":"NCT03181100","phase":"PHASE2","title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-27","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT00565851","phase":"PHASE3","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-06","conditions":"Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":1052},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT01950390","phase":"PHASE2","title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-24","conditions":"Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma","enrollment":169},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":129},{"nctId":"NCT01081262","phase":"PHASE3","title":"Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-12","conditions":"Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma","enrollment":50},{"nctId":"NCT02142803","phase":"PHASE1","title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-20","conditions":"Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma","enrollment":50},{"nctId":"NCT05627635","phase":"PHASE1, PHASE2","title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-05-03","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma","enrollment":20},{"nctId":"NCT03175432","phase":"PHASE2","title":"Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-15","conditions":"BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma","enrollment":29},{"nctId":"NCT00977574","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma","enrollment":349},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03141684","phase":"PHASE2","title":"Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-25","conditions":"Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma","enrollment":63},{"nctId":"NCT03587311","phase":"PHASE2","title":"Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-12","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma","enrollment":96},{"nctId":"NCT05446870","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-25","conditions":"High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma","enrollment":160},{"nctId":"NCT00861705","phase":"PHASE2","title":"Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-21","conditions":"Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7","enrollment":454},{"nctId":"NCT04227028","phase":"PHASE1","title":"Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-03-09","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma","enrollment":5},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT06543576","phase":"PHASE1, PHASE2","title":"External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-07-29","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":35},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT02974621","phase":"PHASE2","title":"Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-12-07","conditions":"Recurrent Glioblastoma","enrollment":70},{"nctId":"NCT04356729","phase":"PHASE2","title":"A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elizabeth Buchbinder, MD","startDate":"2020-08-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma","enrollment":30},{"nctId":"NCT06292286","phase":"NA","title":"Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-11-01","conditions":"Recurrent Ovarian Carcinoma","enrollment":18},{"nctId":"NCT06393751","phase":"PHASE1, PHASE2","title":"Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-31","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT00601900","phase":"PHASE3","title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-09-24","conditions":"Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6","enrollment":394},{"nctId":"NCT02138617","phase":"PHASE2","title":"Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05-06","conditions":"Colon Cancer","enrollment":100},{"nctId":"NCT04761614","phase":"PHASE1","title":"Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Ning Jin","startDate":"2021-04-02","conditions":"Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8","enrollment":13},{"nctId":"NCT01903330","phase":"PHASE2","title":"ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Epitopoietic Research Corporation","startDate":"2014-03","conditions":"Glioblastoma, Gliosarcoma","enrollment":84},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT04164069","phase":"PHASE1","title":"Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab","status":"COMPLETED","sponsor":"Anne Noonan","startDate":"2020-09-02","conditions":"Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8","enrollment":9},{"nctId":"NCT06160206","phase":"PHASE2","title":"Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2024-10-02","conditions":"Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma","enrollment":134},{"nctId":"NCT04456699","phase":"PHASE3","title":"Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-19","conditions":"Metastatic Colorectal Cancer","enrollment":335},{"nctId":"NCT05183984","phase":"PHASE2","title":"Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2022-02-01","conditions":"Ovarian Cancer","enrollment":390},{"nctId":"NCT02873195","phase":"PHASE2","title":"Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2017-07-07","conditions":"Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma","enrollment":133},{"nctId":"NCT02020707","phase":"PHASE1","title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-02-24","conditions":"Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma","enrollment":43},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT01236560","phase":"PHASE2, PHASE3","title":"Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01-26","conditions":"Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma","enrollment":101},{"nctId":"NCT02456857","phase":"PHASE2","title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-12","conditions":"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma","enrollment":17},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT05180422","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis","status":"WITHDRAWN","sponsor":"Criterium, Inc.","startDate":"2022-06-15","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00942331","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-15","conditions":"Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma","enrollment":506},{"nctId":"NCT02921269","phase":"PHASE2","title":"Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-10","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified","enrollment":11},{"nctId":"NCT04753216","phase":"PHASE2","title":"Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2021-03-16","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":3},{"nctId":"NCT05093608","phase":"PHASE1","title":"SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-03","conditions":"Hepatocellular Carcinoma","enrollment":2},{"nctId":"NCT00785291","phase":"PHASE3","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-10-13","conditions":"Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":799},{"nctId":"NCT01229943","phase":"PHASE2","title":"Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-15","conditions":"Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma","enrollment":150},{"nctId":"NCT01609790","phase":"PHASE2","title":"Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-06-04","conditions":"Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma","enrollment":137},{"nctId":"NCT01664182","phase":"PHASE2","title":"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-01","conditions":"Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":41},{"nctId":"NCT02292758","phase":"PHASE2","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2014-12-12","conditions":"Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7","enrollment":36},{"nctId":"NCT00989651","phase":"PHASE1","title":"Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-28","conditions":"Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma","enrollment":431},{"nctId":"NCT01217437","phase":"PHASE2","title":"Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-22","conditions":"Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma","enrollment":108},{"nctId":"NCT00951496","phase":"PHASE3","title":"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-08-11","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma","enrollment":1560},{"nctId":"NCT01532089","phase":"PHASE2","title":"Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2012-03-16","conditions":"EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":88}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"CHEST DISCOMFORT"},{"count":3,"reaction":"HEADACHE"},{"count":2,"reaction":"CHEST PAIN"},{"count":2,"reaction":"DEATH"},{"count":2,"reaction":"FLUSHING"},{"count":2,"reaction":"INFUSION RELATED REACTION"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"NO ADVERSE EVENT"},{"count":2,"reaction":"PAIN"},{"count":2,"reaction":"RASH"}],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MVASI"],"phase":"marketed","status":"approved","brandName":"Bevacizumab-awwb","genericName":"Bevacizumab-awwb","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}